Humira patents take center stage as House panel targets AbbVie pricing

Humira patents take center stage as House panel targets AbbVie pricing

Source: 
BioPharma Dive
snippet: 

Patents protecting AbbVie's inflammatory disease drug Humira in Europe expired two and half years ago, forcing the company to sharply cut its prices as low-cost competitors flooded the region.